HIV-1-dependent HERV-K proteome
HIV-1依赖性HERV-K蛋白质组
基本信息
- 批准号:10005650
- 负责人:
- 金额:$ 27.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-25 至 2022-01-31
- 项目状态:已结题
- 来源:
- 关键词:Amino Acid SequenceAnti-HIV TherapyAntibodiesAntiviral AgentsAntiviral TherapyBiological MarkersBiologyBypassCD4 Positive T LymphocytesCellsClinicalComplexCustomCytotoxic T-LymphocytesDataData AnalysesData SetDiseaseDominant-Negative MutationElementsEndogenous RetrovirusesEnvironmentExpression ProfilingFamilyGenerationsGenetic TranscriptionGenomeGoalsHIVHIV InfectionsHIV-1HealthHumanHuman CharacteristicsHuman GenomeImmune TargetingInfectionInterventionKnowledgeLengthLinkMapsMass Spectrum AnalysisMediatingMethodsMolecularNuclear ExportOpen Reading FramesPatientsPeptidesPharmaceutical PreparationsPlant RootsPotassiumPrimary InfectionProductionProteinsProteomeRNARNA SplicingReagentReportingResearchResolutionRetroelementsRetrovirus ProteinsRoleSourceStructureSystems AnalysisTestingTranscriptTranslationsUp-RegulationWorkanalytical toolbasecell typedata integrationdata visualizationdeep sequencingexomeexperimental studyhigh rewardhigh riskinnovationinsightnovelprotein Kprotein expressionsequencing platformsingle moleculetoolviral RNA
项目摘要
Abstract
During infection, part of the cellular environment rewired by HIV-1 is composed by endogenous retroviruses.
Studies that have revealed the HIV mediated increase of HERV-K HML-2 proteins, underscored HERV-K
potential as an excellent source of antigenic targets for anti-HIV therapy. We have found that during HIV-1
infection of primary CD4+ T-cells, the high expressing HERV-K HML-2 elements are those that are unable to
autonomously produce proteins. This creates a conundrum about which are the elements that are at the root of
HIV-1 dependent HERV-K HML-2 protein production and by what mechanism they achieve it. We will
investigate the mechanism by which HIV-1 mediates HERV-K HML-2 protein upregulation during infection.
Furthermore, the repetitive nature of HERV-K HML-2 family has undermined their study in relation to the effect
they have on HIV-1, as conventional analysis systems are often insufficient. By combining HERV-K-specific
RNA and protein expression analyses we have devised an approach that not only can accurately establish the
HERV-K expression profile of different cell types, but also determines which of those expressed HERV-Ks
produces proteins and peptides. The identity of the specific elements responsible for HERV-K HML-2 protein
expression is essential to investigate the consequences of their expression on HIV-HERV-K interaction, as
small differences in amino acid sequence have been demonstrated to have important repercussions on their
function. Taken together, this proposal will contribute to a better understanding of the relation between HIV-1
infection and HERV-K protein production, and provide the tools to assess specific HERV-K HML-2 as potential
HIV-1-dependent antigenic targets for antiviral therapy.
摘要
在感染过程中,HIV-1重新连接的部分细胞环境由内源性逆转录病毒组成。
研究显示,HIV介导的HERV-K HML-2蛋白增加,强调HERV-K
作为抗HIV治疗的抗原靶点的极好来源的潜力。我们发现在HIV-1感染期间
感染原代CD 4 + T细胞,高表达HERV-K HML-2元件是那些不能
自主生产蛋白质。这就产生了一个难题,即哪些元素是
HIV-1依赖的HERV-K HML-2蛋白的产生以及它们通过什么机制实现它。
研究HIV-1在感染过程中介导HERV-K HML-2蛋白上调的机制。
此外,HERV-K HML-2家族的重复性破坏了他们关于HERV-K HML-2效应的研究。
他们对HIV-1的分析,因为传统的分析系统往往是不够的。通过结合HERV-K特异性
RNA和蛋白质表达分析,我们设计了一种方法,不仅可以准确地建立
不同细胞类型的HERV-K表达谱,但也决定了哪些表达HERV-Ks
产生蛋白质和肽。HERV-K HML-2蛋白特异性元件的鉴定
表达对于研究其表达对HIV-HERV-K相互作用的后果至关重要,
已经证明氨基酸序列中的微小差异对它们的功能具有重要影响。
功能总之,这一建议将有助于更好地了解艾滋病毒-1之间的关系
感染和HERV-K蛋白的产生,并提供工具来评估特定的HERV-K HML-2作为潜在的
抗病毒治疗的HIV-1依赖性抗原靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LUBBERTUS C MULDER其他文献
LUBBERTUS C MULDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LUBBERTUS C MULDER', 18)}}的其他基金
HERV proteogenomics of narcotic-driven HIV latency
麻醉药驱动的 HIV 潜伏期的 HERV 蛋白质基因组学
- 批准号:
10675341 - 财政年份:2023
- 资助金额:
$ 27.16万 - 项目类别:
Impact of HERV-K expression on HIV-1 life cycle
HERV-K 表达对 HIV-1 生命周期的影响
- 批准号:
9037680 - 财政年份:2014
- 资助金额:
$ 27.16万 - 项目类别:
Impact of HERV-K expression on HIV-1 life cycle
HERV-K 表达对 HIV-1 生命周期的影响
- 批准号:
8957700 - 财政年份:2014
- 资助金额:
$ 27.16万 - 项目类别:
Impact of HERV-K expression on HIV-1 life cycle
HERV-K 表达对 HIV-1 生命周期的影响
- 批准号:
8918002 - 财政年份:2014
- 资助金额:
$ 27.16万 - 项目类别:
Impact of HERV-K expression on HIV-1 life cycle
HERV-K 表达对 HIV-1 生命周期的影响
- 批准号:
8730823 - 财政年份:2014
- 资助金额:
$ 27.16万 - 项目类别:
Impact of HERV-K expression on HIV-1 life cycle
HERV-K 表达对 HIV-1 生命周期的影响
- 批准号:
9309282 - 财政年份:2014
- 资助金额:
$ 27.16万 - 项目类别:
Genome stability function of APOBEC3 retroviral restriction factors
APOBEC3逆转录病毒限制因子的基因组稳定性功能
- 批准号:
8309218 - 财政年份:2011
- 资助金额:
$ 27.16万 - 项目类别:
Genome stability function of APOBEC3 retroviral restriction factors
APOBEC3逆转录病毒限制因子的基因组稳定性功能
- 批准号:
8209618 - 财政年份:2011
- 资助金额:
$ 27.16万 - 项目类别:
Genome stability maintenance factors in early HIV-1 infection
早期HIV-1感染中的基因组稳定性维持因素
- 批准号:
7846591 - 财政年份:2009
- 资助金额:
$ 27.16万 - 项目类别:
Genome stability maintenance factors in early HIV-1 infection
早期HIV-1感染中的基因组稳定性维持因素
- 批准号:
7499735 - 财政年份:2007
- 资助金额:
$ 27.16万 - 项目类别:
相似海外基金
Pediatric Immune Correlates of Early Anti-HIV Therapy
早期抗 HIV 治疗的儿科免疫相关性
- 批准号:
8049900 - 财政年份:2010
- 资助金额:
$ 27.16万 - 项目类别:
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy
靶向 PI3K/Akt 细胞生存途径作为新型抗 HIV 疗法
- 批准号:
8006433 - 财政年份:2009
- 资助金额:
$ 27.16万 - 项目类别:
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy
靶向 PI3K/Akt 细胞生存途径作为新型抗 HIV 疗法
- 批准号:
8204745 - 财政年份:2009
- 资助金额:
$ 27.16万 - 项目类别:
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy
靶向 PI3K/Akt 细胞生存途径作为新型抗 HIV 疗法
- 批准号:
7743007 - 财政年份:2009
- 资助金额:
$ 27.16万 - 项目类别:
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy
靶向 PI3K/Akt 细胞生存途径作为新型抗 HIV 疗法
- 批准号:
7622243 - 财政年份:2009
- 资助金额:
$ 27.16万 - 项目类别:
Analysis of within-patient HIV-1 evolution and drug resistance mechanismsunder anti-HIV therapy
抗HIV治疗下患者体内HIV-1进化及耐药机制分析
- 批准号:
19510208 - 财政年份:2007
- 资助金额:
$ 27.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
From Total Synthesis-Inspired Methodology to Anti-HIV therapy
从全合成启发的方法到抗 HIV 治疗
- 批准号:
EP/E055273/1 - 财政年份:2007
- 资助金额:
$ 27.16万 - 项目类别:
Fellowship
Pediatric Immune Correlates of Early Anti-HIV Therapy
早期抗 HIV 治疗的儿科免疫相关性
- 批准号:
7187354 - 财政年份:2005
- 资助金额:
$ 27.16万 - 项目类别:
Establishment of Rev based anti-HIV therapy.
建立基于 Rev 的抗 HIV 疗法。
- 批准号:
17591037 - 财政年份:2005
- 资助金额:
$ 27.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Pediatric Immune Correlates of Early Anti-HIV Therapy
早期抗 HIV 治疗的儿科免疫相关性
- 批准号:
6843339 - 财政年份:2005
- 资助金额:
$ 27.16万 - 项目类别: